TransCode Therapeutics (RNAZ) Insider Trading & Ownership $3.52 +0.17 (+5.07%) As of 01/21/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TransCode Therapeutics (NASDAQ:RNAZ) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.80%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$142,560.00Number OfInsiders Selling(Last 3 Years)0 Get RNAZ Insider Trade Alerts Want to know when executives and insiders are buying or selling TransCode Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RNAZ Insider Buying and Selling by Quarter TransCode Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/28/2023Robert Michael DudleyCEOBuy74$673.20$49,816.80 9/28/2023Thomas A FitzgeraldCFOBuy37$673.20$24,908.40 6/20/2023Robert Michael DudleyCEOBuy5$3,366.00$16,830.00 6/9/2023Robert Michael DudleyCEOBuy14$3,643.20$51,004.80 9/14/2022Robert Michael DudleyCEOBuy0$30,360.00$0.00 (Data available from 1/1/2013 forward) RNAZ Insider Trading Activity - Frequently Asked Questions Who is on TransCode Therapeutics's Insider Roster? The list of insiders at TransCode Therapeutics includes Robert Michael Dudley, and Thomas A Fitzgerald. Learn more on insiders at RNAZ. What percentage of TransCode Therapeutics stock is owned by insiders? 2.80% of TransCode Therapeutics stock is owned by insiders. Learn more on RNAZ's insider holdings. Which TransCode Therapeutics insiders have been buying company stock? The following insiders have purchased RNAZ shares in the last 24 months: Robert Michael Dudley ($117,651.60), and Thomas A Fitzgerald ($24,908.40). How much insider buying is happening at TransCode Therapeutics? Insiders have purchased a total of 130 RNAZ shares in the last 24 months for a total of $142,560.00 bought. TransCode Therapeutics Key ExecutivesMr. Thomas A. Fitzgerald M.B.A. (Age 72)Interim CEO, CFO, President, VP of Administration & Director Compensation: $358.14kDr. Philippe P. Calais Ph.D. (Age 65)Pharm., Pharm.D., Executive Chairman of the Board Compensation: $102.5kDr. Zdravka Medarova Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Dr. Anna Moore Ph.D. (Age 62)Co-Founder, Scientific Advisor & Member of Scientific Advisory Board Ms. Susan Duggan M.B.A.R.N., Senior Vice President of OperationsDr. Daniel R. Vlock M.D. (Age 72)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Cyclerion Therapeutics Insider Trading Eagle Pharmaceuticals Insider Trading Soligenix Insider Trading Orgenesis Insider Trading Viracta Therapeutics Insider Trading CNS Pharmaceuticals Insider Trading Galecto Insider Trading Kazia Therapeutics Insider Trading Adial Pharmaceuticals Insider Trading Genprex Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:RNAZ) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredForget 99.999% of Stocks… Do This insteadThis might sound crazy to say... But FORGET most stocks. Because I have a different strategy... One t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.